LUIS ALBERTO
MENCHÉN VISO
Profesor asociado de Ciencias de la Salud
Hospital Universitario Reina Sofia
Córdoba, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Reina Sofia (11)
2023
-
Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP
Journal of Clinical Medicine, Vol. 12, Núm. 14
-
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247
2021
-
Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu
Journal of Clinical Medicine, Vol. 10, Núm. 19
2020
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
Characteristics of inflammatory bowel disease in patients of Roma/Gypsy ethnicity. A case-control study
Digestive and Liver Disease, Vol. 51, Núm. 5, pp. 669-674
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
2013
-
Does smoking influence Crohn's disease in the biologic era? the TABACROHN study
Inflammatory Bowel Diseases, Vol. 19, Núm. 1, pp. 23-29
-
High smoking cessation rate in Crohn's disease patients after physician advice - The TABACROHN Study
Journal of Crohn's and Colitis, Vol. 7, Núm. 3, pp. 202-207
2012
-
Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease
Alimentary Pharmacology and Therapeutics, Vol. 35, Núm. 12, pp. 1379-1385